{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Eiger+BioPharmaceuticals",
    "query": {
      "sponsor": "Eiger BioPharmaceuticals"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Eiger+BioPharmaceuticals&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T15:26:06.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03373435",
      "title": "Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postbariatric Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "exendin 9-39",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eiger BioPharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-03-19",
      "completion_date": "2019-03-15",
      "has_results": true,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03373435"
    },
    {
      "nct_id": "NCT02664558",
      "title": "A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "ubenimex",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eiger BioPharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 61,
      "start_date": "2016-04",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02664558"
    },
    {
      "nct_id": "NCT04343976",
      "title": "Pegylated Interferon Lambda Treatment for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "COVID"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon lambda",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raymond Chung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-06-22",
      "completion_date": "2021-07-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04343976"
    },
    {
      "nct_id": "NCT02736149",
      "title": "Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "ubenimex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eiger BioPharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2016-12",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-18",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 26,
      "location_summary": "Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02736149"
    },
    {
      "nct_id": "NCT02700529",
      "title": "Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphedema"
      ],
      "interventions": [
        {
          "name": "ubenimex",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eiger BioPharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 54,
      "start_date": "2016-06",
      "completion_date": "2019-02",
      "has_results": true,
      "last_update_posted_date": "2023-01-18",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Orlando, Florida • Columbus, Ohio",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02700529"
    },
    {
      "nct_id": "NCT04652479",
      "title": "Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Hyperinsulinemic Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Avexitide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Tracey McLaughlin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-06-21",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04652479"
    },
    {
      "nct_id": "NCT02771574",
      "title": "Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Bariatric Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Lyo avexitide",
          "type": "DRUG"
        },
        {
          "name": "Liq avexitide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tracey McLaughlin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 19,
      "start_date": "2016-05",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02771574"
    },
    {
      "nct_id": "NCT04344600",
      "title": "Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sars-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "Peginterferon lambda alfa-1a subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-06-29",
      "completion_date": "2021-09-24",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04344600"
    },
    {
      "nct_id": "NCT00916747",
      "title": "Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progeria"
      ],
      "interventions": [
        {
          "name": "Lonafarnib, Zoledronic Acid, and Pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 85,
      "start_date": "2009-08",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916747"
    },
    {
      "nct_id": "NCT05070364",
      "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis Delta Virus"
      ],
      "interventions": [
        {
          "name": "Peginterferon Lambda-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eiger BioPharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-12-21",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-28T15:26:06.281Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Redwood City, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05070364"
    }
  ]
}